Hydralazine
Loading...Hydralazine Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
In a few patients hydrALAzine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydrALAzine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary. (See PRECAUTIONS, Laboratory Tests .)
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Essential hypertension, alone or as an adjunct.
History
There is currently no drug history available for this drug.
Other Information
HydrALAzine hydrochloride, USP, is an antihypertensive, for oral administration. Its chemical name is 1-hydrazinophthalazine monohydrochloride, and its structural formula is:
HydrALAzine hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275°C, with decomposition, and has a molecular weight of 196.64.
Each tablet for oral administration contains 10 mg, 25 mg, 50 mg or 100 mg hydrALAzine hydrochloride, USP. Tablets also contain anhydrous lactose, microcrystalline cellulose, sodium starch glycolate, stearic acid and FD&C Yellow #6.
Sources
Hydralazine Manufacturers
-
Cardinal Health
![Hydralazine Tablet [Cardinal Health]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Hydralazine | Cardinal Health
Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2 to 4 days, increase to 25 mg four times daily for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg four times daily. For maintenance, adjust dosage to the lowest effective levels.
The incidence of toxic reactions, particularly the L.E. cell syndrome, is high in the group of patients receiving large doses of hydrALAzine.
In a few resistant patients, up to 300 mg of hydrALAzine daily may be required for a significant antihypertensive effect. In such cases, a lower dosage of hydrALAzine combined with a thiazide and/or reserpine or a betablocker may be considered. However, when combining therapy, individual titration is essential to ensure the lowest possible therapeutic dose of each drug.
Login To Your Free Account